|Bid||118.23 x 100|
|Ask||119.03 x 100|
|Day's Range||114.52 - 118.99|
|52 Week Range||96.18 - 149.34|
|PE Ratio (TTM)||60.37|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||157.10|
NEW YORK, Feb. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Jack ...
This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Over the last one-month, outflows of investor capital in ETFs holding ALXN totaled $2.27 billion.
Alexion Pharmaceuticals is moving its headquarters from Connecticut to Boston later this year, but at least two top executives won’t be coming along. Alexion (ALXN) said in its annual filing on Thursday that its general counsel, John Moriarty, and head of global government affairs, Heidi Wagner, “have chosen not to relocate” to Boston and will be leaving the company this month.
Alexion reported adjusted income of $1.48 per share on sales of $909.7 million for its fourth quarter, while Alnylam reported adjusted losses of $1.48 per share.
Alexion Pharmaceuticals Inc (NASDAQ:ALXN) is trading with a trailing P/E of 51.9x, which is higher than the industry average of 27x. Although some investors may jump to the conclusion thatRead More...
Alexion (ALXN) surpass earnings and sales estimates in the fourth quarter of 2017. The company received FDA approval for label expansion of Soliris in the United States.
NEW YORK, NY / ACCESSWIRE / February 8, 2018 / Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 8, 2018 at 10:00 ...
On a per-share basis, the New Haven, Connecticut-based company said it had net income of 13 cents. Earnings, adjusted for restructuring costs and amortization costs, came to $1.48 per share. The results ...
Alexion Pharmaceuticals, Inc. today announced financial results for the fourth quarter and full year of 2017. Total revenues for the full year of 2017 were $3.551 billion, a 15 percent increase compared to 2016.
Let's take a look at which of these biotech companies, Alexion (ALXN) or Regeneron (REGN) has an edge ahead of their Q4 release.
Alexion Pharmaceuticals (ALXN) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Alexion Pharmaceuticals, Inc. announced today that the combined interim data from two ongoing open-label studies, VITAL and CL-08, show a 3-year survival estimate of 68% in infants with rapidly progressive lysosomal acid lipase deficiency treated with Kanuma® .1 Of the 19 infants who were enrolled in the studies, 7 infants are surviving and have reached 3 years of age while an additional 6 infants ...
Alexion Pharmaceuticals, Inc. today announced that Judith A. Reinsdorf, J.D., has been appointed to the Company’s Board of Directors. Ms. Reinsdorf is an accomplished executive with a strong background in corporate governance and broad expertise in managing corporate and legal affairs for large public companies.